Agreements reached under this partnership
Capital and Business Alliance- 1
The additional investment is expected to be used by Isofol for the global clinical development of SP-05 and is considered to be directly related to the development of SP-05 for the Company, the Japanese rights holder for SP-05.
- 2
Closer collaboration with Isofol is expected in future SP-05 development activities.
- 3
The Company is expected to benefit from part of the economic value generated by progress in the development of SP-05 in regions outside Japan.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The investment is expected to have a positive impact over the medium to long term through progress in the development of SP-05, but is not expected to affect consolidated results for fiscal 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Isofol Medical AB |
| Alliance partner's business activities | Licensor of SP-05 rights, development partner, and global rights holder |
| Alliance partner's location | Sweden |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | The additional investment is expected to be used by Isofol for the global clinical development of SP-05 and is considered to be directly related to the development of SP-05 for the Company, the Japanese rights holder for SP-05., Closer collaboration with Isofol is expected in future SP-05 development activities., The Company is expected to benefit from part of the economic value generated by progress in the development of SP-05 in regions outside Japan. |
| Number of shares acquired | 2,083,332 shares; the percentage of total shares outstanding will be 2.6%, representing the Company's ownership interest following the additional subscription |
| Acquisition price | 0.48 SEK per share (Swedish krona) |
| Shareholding ratio | Not disclosed → 2.6% |
| Shareholding Policy | No lock-up conditions will apply to the Company's shareholding. |
| Share Acquisition Date and Payment Date | March 2026 (scheduled timing for exercising the share acquisition rights and completing the additional subscription) |
| Impact on Business Performance | The investment is expected to have a positive impact over the medium to long term through progress in the development of SP-05, but is not expected to affect consolidated results for fiscal 2026. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The additional investment is expected to be used for the global clinical development of SP-05 and is therefore directly related to SP-05's development; closer collaboration with Isofol is expected in future development activities; and the Company is expected to benefit from part of the economic value generated by progress in the development of SP-05 in regions outside Japan.